• Optimind (OMND) provides an update on Health Canada’s Dealer License under joint-venture with Manitari Pharma
  • Manitari Pharma has begun permitting and planning the build-out of its facility under the guidance of Health Canada
  • Health Canada has approved Manitari Pharma’s plan, pending final inspection, to install a Security Level 3 vault and grow rooms
  • Optimind offers psychedelic-assisted treatment to patients suffering from PTSD, anxiety, depression, and other mental illnesses.
  • Optimind Pharma Corp. (OMND) is in the grey, trading at C$0.14 at 11:23 am EST

Optimind Pharma (OMND) updated its joint venture with Manitari Pharma Corporation, which is 40 per cent owned by Optimind.

Manitari Pharma has begun permitting and planning the build-out of its facility by the guidance of Health Canada.

Health Canada has approved Manitari Pharma’s plan, pending final inspection, to install a Security Level 3 vault and grow rooms based on the Health Canada Directive on Physical Security Requirements for Controlled Substances and Drugs.

A Dealer’s License would permit Manitari Pharma to perform the following activities: procure controlled substances, including by import, synthesis, propagation, cultivation, and harvesting of psychedelic mushrooms for Psilocybin extraction and more.

“[…] Optimind looks forward to continuing working with Manitari Pharma as it develops treatments for qualifying patients that desperately need psychedelic-enhanced therapy to get better,” commented Tomas Sipos, Chief Executive Officer at Optimind.

“This is vital in expanding our mission in ensuring the future mental health of First Nations and the global community at large,” commented Anna Freeman, Chief Executive Officer at Manitari Pharma.

Optimind offers psychedelic-assisted treatment to patients suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine-assisted therapy and other psychedelic-enhanced psychotherapy modalities.

Optimind is an emerging provider of psychedelic therapies. 

Optimind Pharma Corp. (OMND) is in the grey, trading at C$0.14 at 11:23 am EST.


More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.